Phase II Multicenter, Open-label, Clinical and Pharmacokinetic Study of Zalypsis (PM00104) in Patients With Unresectable Locally Advanced and/or Metastatic Ewing Family of Tumors (EFT) Progressing After at Least One Prior Line of Chemotherapy.

Trial Profile

Phase II Multicenter, Open-label, Clinical and Pharmacokinetic Study of Zalypsis (PM00104) in Patients With Unresectable Locally Advanced and/or Metastatic Ewing Family of Tumors (EFT) Progressing After at Least One Prior Line of Chemotherapy.

Completed
Phase of Trial: Phase II

Latest Information Update: 29 Apr 2015

At a glance

  • Drugs PM 00104 (Primary)
  • Indications Ewing's sarcoma
  • Focus Pharmacogenomic; Therapeutic Use
  • Most Recent Events

    • 04 Jun 2012 Actual patients number is 17 as reported by ClinicalTrials.gov.
    • 04 Jun 2012 Actual end date (Apr 2012) added as reported by ClinicalTrials.gov.
    • 04 Jun 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top